Efficacy News and Research

RSS

Novel inhibitor to fight metastatic prostate cancer shows promise

When prostate cancer spreads it is often a deadly disease, but now a Stony Brook University-led research team believes a new approach that inhibits a specific fatty acid binding protein (FABP) may be the key to halting disease progression.

30 Jan 2020

Research reveals key molecular target for colorectal cancer therapy

Serine racemase is a multifunctional enzyme that carries out several different reactions in human cells, including the conversion of L-serine into pyruvate.

29 Jan 2020

New strategy using organoids to study childhood brain tumors

A new study reports the creation of in vitro models of brain tumors in children using organoids derived from stem cells, which will help to screen new drugs for efficacy and thus improve the rate of drug development. The study, titled 'Modeling medulloblastoma in vivo and with human cerebellar organoids,' is published in the journal Nature Communications.

29 Jan 2020

Robotic search for drugs that block sperm motility

The hunt for the first male contraceptive pill is on, and scientists at Dundee University may have the needed tool to find it – a robotic screening system.

29 Jan 2020

A single dose of magic mushroom compound reduces anxiety and depression among cancer patients

Magic mushrooms are wild or cultivated mushrooms containing psilocybin, which is a naturally occurring hallucinogenic and psychoactive compound. A single dose of psilocybin provides long-term relief of anxiety and depression in cancer patients, a new study found.

29 Jan 2020

New way to treat stroke using an already FDA-approved drug shows promise

Stroke is the third leading cause of death and disability in the United States. More than 87 percent are ischemic strokes, caused by obstruction of one or more cerebral arteries. With limited progress in developing treatments, there is a critical need for neuroprotective agents to effectively treat stroke.

29 Jan 2020

Researchers develop new strategy to study childhood brain tumors

Researchers are at work to find effective treatments to help young patients with brain tumors. Hundreds of brain organoids have been developed in the laboratories of the University of Trento to understand the genetic mechanisms responsible for these hard to treat diseases.

29 Jan 2020

Analysis of Postmortem Microbes using Gas Chromatography

In this interview, Katelynn Perrault, from Chaminade University of Honolulu talks to News-Medical and Life Sciences about her research into using Multidimensional Gas Chromatography to achieve odor profiling of postmortem microbes.

From Pittcon 29 Jan 2020

FDA issues stern warning to Purell hand sanitizer maker

The U.S. Food and Drug Administrator has issued a strict warning to Purell-maker GOJO Industries, which claims it hand sanitizers can kill pathogens that cause illness in as little as 15 seconds.

29 Jan 2020

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

Study shows wide variability in cost for orthobiologic therapies

The use of orthobiologics is a hot trend in orthopedics, but new research from the University of Alabama at Birmingham shows wide variability in cost for these therapies.

28 Jan 2020

The challenge of new antibiotic discovery

It is important to discover antibiotic drugs and to bring them to clinical use, a task made all the more urgent by the increase in the number of infections that are resistant to existing antibiotics. However, this task is a formidable one.

28 Jan 2020

Research provides insights about sex- and gender-specific aspects of medicine

At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".

28 Jan 2020

Parkinson's Foundation announces first-ever Physical Therapy Faculty Award

The Parkinson's Foundation announced that it has awarded its first-ever Parkinson's Foundation Physical Therapy Faculty Award to three physical therapists, totaling $30,000.

28 Jan 2020

New gene correction therapy for hereditary muscular disease among children

Duchenne type muscular dystrophy is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of twelve and reducing life expectancy.

27 Jan 2020

Call for FDA to withdraw preterm birth drug divides doctors and insurers

Doctors fear that the only drug approved to prevent preterm birth, the nation’s leading cause of infant mortality and disability, will no longer be available to expectant mothers.

27 Jan 2020

Medtronic: RCT demonstrates profound back pain relief with DTM therapy

Medtronic plc today announced three-month results from a large, multicenter randomized controlled trial showing statistically significant (p=0.0009) and superior back pain relief with Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) compared to conventional SCS.

From Medtronic 27 Jan 2020

Prescription drug bumetanide could help treat autism

A new drug called bumetanide, which is used to treat edema, shows promise in treating some symptoms of autism in young children, while not showing significant adverse effects. The study was published in January 2020 in the journal Translational Psychiatry.

26 Jan 2020

Scientists discover new drug target for prostate cancer in the non-coding genome

Scientists at Princess Margaret Cancer Centre have identified the drivers of a crucial gene involved in prostate cancer, revealing new targets for drug design.

23 Jan 2020

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.

22 Jan 2020